详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Recent Advances in Targeted Therapy for Glioma.

文献详情

资源类型：

作者：

机构： [1]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. [2]Neurosurgical Institute, Heilongjiang Academy of Medical Science, Harbin, China. [3]Neuroscience Institute, Sino-Russian Medical Research Center, Harbin, China. [4]Glioma Cooperative Group (CGCG), Beijing, China.

出处：

DOI：

ISSN：

摘要：

Gliomas are the most common primary malignant brain tumors, which have a universally fatal outcome. Current standard treatment for glioma patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients. By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine kinase receptors including EGFR, PDGFR and other crucial signal pathways such as PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy and stem cell therapy also brought numerous strategies to glioma treatment. This article reviewed the researches focused on the advanced strategies of various target therapies for improving the glioma treatment efficacy, and discussed the challenges and future directions for glioma therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 2 区药物化学 2 区药学 3 区生化与分子生物学

最新[2023]版

：

大类 | 4 区医学

小类 | 3 区生化与分子生物学 3 区药物化学 3 区药学

第一作者：

第一作者机构： [1]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. [2]Neurosurgical Institute, Heilongjiang Academy of Medical Science, Harbin, China. [3]Neuroscience Institute, Sino-Russian Medical Research Center, Harbin, China. [4]Glioma Cooperative Group (CGCG), Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：